Lilly to pay up to $660M in new deal with PRISM BioLab; Boehringer partners with Phenomic AI
Plus, news about Ascendis Pharma, Biolexis, Aperiam Bio, BiomX and Italfarmaco:
Eli Lilly inks new deal with PRISM BioLab: The Indianapolis Big Pharma is making an undisclosed upfront payment and could eventually pay up to $660 million to the Japanese company for work on protein-protein interactions. The pact starts with one target, and Lilly could add two more. The companies kept all other details under wraps. PRISM already works with companies like Eisai, Boehringer Ingelheim, Merck KGaA and Roche. — Kyle LaHucik
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.